Abbott, Stone Drug's exclusive response to layoffs, analyze the three main reasons for multinational drug companies to lay off workers

Medicines Network January 20th, January 17th, Abbott China's all-ansu OTC team was laid off the newsAccording to reports, the layoffs involved nearly 200 people nationwide, including the vast majority of all-anan product line of provincial and regional managers, and the layoffs were completed by December 31, 2016in response to the news, Abbott's Chinese public relations source told E Pharmaceuticals: "The rumors are partly untrue." The AllAns product line has previously been handed over to external service providers, and Abbott China would not comment on the adjustment of its own resources by external service providersBut Mr Abbott refused to reveal who the mysterious "external service provider" wasE drug manager reporter through the industry news learned: this receiver is stone drug groupShi Pharmaceutical Group Dong Mi Song Hongchao in an interview with E drug manager sin admitted: The whole ansin product line is a subsidiary of The Ishiguro Pharmaceutical Group, The specific operation of the companywhat exactly is the product line of The Story's protagonist, Oyi and The Sales Company, and Quan Ansu? Has this CSO model become more and more important in the strategy of multinational pharmaceutical companies in China? What are the reasons for the increasing number of layoffs in China?for employees in China'spharmaceutical
industry, multinational pharmaceutical enterprises have been one of the best career choices, whether it is pharmaceutical representatives, product managers, medical departments and other important industrial chain roles to enter the Chinese market, or pay treatment, welfare system, training system and other institutional construction, multinational pharmaceutical enterprises have been China's pharmaceutical industry leading groupbut that advantage began to blur as industry trends changedFirst of all, from the salary treatment, has been overtaken by many domestic pharmaceutical companies; secondly, from the rising space of career development, private pharmaceutical companies can give these first- and second-generation pharmaceutical professional managers more room to rise;Portal: "Downsizing!" Layoffs! Layoffs! What is theand protagonist of the 2016 Pharmaceutical Company Layoffs"?public information shows that the European-Italian and sales company is the establishment of the Stone Pharmaceutical Group' European-Italian and brand control center, the general manager is Chen HaixiangIn 2016, Euro-Italian and in the field of chronic disease and "Internet-plus medicine" have been laid out, from which this is a match for Abbott's AllAns OTC products Abbott's whole-nutrition formula, which is a nutritional supplement for postoperative rehabilitation patients and middle-aged and elderly people, entered China in 2014 According to industry insiders, Quan Ansu's domestic sales coverage is relatively good, especially in the first and second-tier cities otC and in-hospital sales channels are performing well Abbott China's explanation for all the original team layoffs in the All Ansu product line is that this is the situation that followed outsourcing and therefore has nothing to do with Abbott China But Mr Abbott added: "China is an important market for Abbott and we have confidence in the Chinese market and continue to invest in business development." "
2
, multinational pharmaceutical companies to lay off the three main reasons
the last two years multinational pharmaceutical companies layoffs are not uncommon In the past year, companies including Novartis, NovonorNor Nordisk, Roche, Boxei Schippers (BMS), Mersadon, Sanofi, Uber, GlaxoSmithKline and Johnson and Johnson have reported job cuts combed down, there are three main reasons for the layoffs in multinational pharmaceutical companies: first, the company's global strategic adjustment triggered layoffs As a result of the global strategic transformation, BM
S has made more than one layoff in China in the past two years, and in 2014 it launched a 1,000-person layoff in its pharmaceutical delegation team, involving almost all business units including diabetes, liver disease, oncology, cardiovascular, OTC , and sales support; the second is that mergers and acquisitions are the result of job cuts, which are also common A series of Pfizer mergers and acquisitions in the past have triggered job cuts the third is also the recent "product line outsourcing" in China caused by the "unusual collective separation." It is worth noting that in 2016 multinational pharmaceutical companies in China lay off more prominent features, some multinational pharmaceutical companies to sell non-core business divestitures to the right Chinese receivers or partners, thereby triggering personnel changes, Lilly, AstraZeneca, Youshia and other companies are so, these are global strategies, may not have anything to do with the performance of China In December 2016, for example, The Belgian pharmaceutical company Ushibi announced that it was outsourcing its immune product Panfusu to Shanghai Smecon Bio for sale Therefore, with PanFushu-related U.S times than personnel, in addition to part of the transfer to Smykang, the rest of the people can only regret leaving the scene the aura of being a foreign company's personnel fading, and working in a foreign company is no longer a stable job Especially in the past two years, foreign pharmaceutical companies for various reasons for the strategic transformation, mergerand and acquisition integration and the division of business sectors, spin-off, spin-off, is triggering a more volatile state At the same time, China's domestic policy and environment are also changing dramatically, how to achieve more rapid, sustainable and profit-maximizing development in China, is the top priority of every multinational company in thinking